CeriBell, Inc., a company specializing in seizure diagnostics, has filed for an upsized initial public offering (IPO) of 10.6 million shares, with a revised price range set between $16 and $17 per share. The company aims for a valuation of up to $578 million following the offering. Initially, the offering was set for 6.7 million shares at a price range of $14 to $16. However, the underwriters amended the terms, increasing the share count and adjusting the price range. On October 11, CeriBell priced its IPO at $17, the high end of the revised range, and is set to debut on the Nasdaq Exchange. Early trading indications suggest a strong performance, with shares up 35% following the pricing.